Roswell Park Comprehensive Cancer Center | Strategic Alliance Partners

Latest from Roswell Park Comprehensive Cancer Center


TRT in Patients With Prostate Cancer on Active Surveillance: Are We Really Putting Gas on Fire?

December 18, 2023

Investigators hypothesized that testosterone replacement does not have a negative impact on the oncologic outcomes of treatment-naive patients with prostate cancer on surveillance and they performed a retrospective review of an institutional active surveillance prostate cancer database.

FDA Panel Votes Sufficient Evidence Available to Support EFS Benefit of Eflornithine in Pediatric High-Risk Neuroblastoma

October 06, 2023

In a 14-to-6 vote, the FDA’s Oncologic Drugs Advisory Committee voted sufficient evidence has been provided to demonstrate the event-free survival benefit of eflornithine to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma.

Retrospective Study Associates Alprazolam With Improved PFS in Pancreatic Cancer

September 05, 2023

The benzodiazepines lorazepam and alprazolam had differing effects on progression-free survival (PFS) outcomes among patients with pancreatic cancer, with lorazepam demonstrating an association with decreased PFS and alprazolam prolonging PFS.